Company intelligence / Profile preview
Yifan Pharmaceutical
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Commercial
Overview
Yifan has a diversified pipeline with over 30 marketed drugs and more than 20 clinical trials ongoing. Recent approvals include Ryzneuta for neutropenia in the EU. The company is advancing several innovative biologics into global clinical development across liver diseases, oncology, endocrinology/metabolic disorders, pediatrics and infectious diseases. Their platforms support both novel drug discovery and biosimilar development.
- Therapeutic areas
- OncologyEndocrinologyImmunologyHematologyPsychiatryGastroenterologyInfectious Diseases
- Modalities
- Small moleculeBiologicSynthetic biologicTraditional Chinese medicine (TCM)
- Industry
- Biotech
Drug pipeline
21 assets20 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Yifan Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yifan Pharmaceutical.